NeurAxis, Inc. (NRXS) Financial Ratios
6 years of historical data (2020–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
23.51
↑+135% vs avg
5yr avg: 10.00
30Y Low7.9·High12.1
ROE
↑
-285.4%
↓+76% vs avg
5yr avg: -1168.7%
30Y Low-285%·High-227%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NRXS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
NeurAxis, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $94M | $41M | $16M | $17M | — | — | — |
| Enterprise Value | $94M | $41M | $13M | $17M | — | — | — |
| P/E Ratio → | -9.26 | — | — | — | — | — | — |
| P/S Ratio | 26.26 | 11.55 | 6.05 | 6.83 | — | — | — |
| P/B Ratio | 23.51 | 12.13 | 7.86 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NRXS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 11.61 | 4.85 | 6.89 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
NRXS Profitability
Margins and return-on-capital ratios measuring operating efficiency
NeurAxis, Inc. earns an operating margin of -219.4%. Operating margins have expanded from -270.9% to -219.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -285.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 84.2% | 84.2% | 86.5% | 87.7% | 88.9% | 82.8% | 75.1% |
| Operating Margin | -219.4% | -219.4% | -266.5% | -270.9% | -125.6% | -109.1% | -213.5% |
| Net Profit Margin | -218.5% | -218.5% | -306.8% | -594.6% | -178.0% | -111.3% | -193.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -285.4% | -285.4% | -2480.5% | — | — | -740.3% | -226.7% |
| ROA | — | — | -312.9% | -1469.9% | -426.6% | -170.6% | -133.6% |
| ROIC | -477.9% | -477.9% | — | — | — | — | — |
| ROCE | — | — | -1509.8% | — | — | -532.0% | -231.4% |
NRXS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.23 | — | — | — | 0.19 |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.06 | -1.56 | — | — | — | -0.96 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -23.80 | -1.24 | -8.08 | -80.43 | -54.43 |
NRXS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio has improved from 0.13x to 1.75x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | — | — | 1.75 | 0.13 | 0.07 | 0.34 | 2.44 |
| Quick Ratio | — | — | 1.74 | 0.12 | 0.06 | 0.32 | 2.33 |
| Cash Ratio | — | — | 1.52 | 0.04 | 0.04 | 0.23 | 1.88 |
| Asset Turnover | — | — | 0.56 | 4.83 | 1.81 | 3.58 | 0.69 |
| Inventory Turnover | — | — | 8.17 | 14.30 | 6.17 | 11.94 | 4.50 |
| Days Sales Outstanding | — | — | 33.24 | 10.86 | 23.71 | 15.47 | 58.87 |
NRXS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
NeurAxis, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $9M | $7M | $6M | $8M | $5M | $5M |
Peer Comparison
Compare NRXS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NRXSYou | $94M | -9.3 | — | — | 84.2% | -219.4% | -285.4% | -477.9% | — |
 LIVN | $4B | -15.9 | 15.4 | 22.4 | 67.7% | 14.4% | -19.2% | 11.5% | 2.0 |
 ELMD | $222M | 31.2 | 19.1 | 20.1 | 78.1% | 15.1% | 17.2% | 25.6% | 0.0 |
 STIM | $128M | -3.1 | — | — | 48.5% | -21.1% | -134.4% | -26.6% | — |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 ABT | $151B | 11.4 | 15.8 | 23.8 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 BSX | $84B | 29.2 | 25.3 | 23.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 GKOS | $8B | -40.9 | — | — | 77.5% | -17.1% | -26.4% | -9.2% | — |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 HSIC | $8B | 21.6 | 10.9 | 14.1 | 29.1% | 5.7% | 8.3% | 7.1% | 3.4 |
 MMSI | $4B | 29.3 | 13.1 | 17.2 | 48.7% | 12.2% | 8.7% | 7.2% | 2.8 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See NRXS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NRXS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NRXS vs LIVN
Side-by-side business, growth, and profitability comparison vs LivaNova PLC.
Start ComparisonNRXS — Frequently Asked Questions
Quick answers to the most common questions about buying NRXS stock.
What is NeurAxis, Inc.'s P/E ratio?
NeurAxis, Inc.'s current P/E ratio is -9.3x. This places it at the 50th percentile of its historical range.
What is NeurAxis, Inc.'s ROE?
NeurAxis, Inc.'s return on equity (ROE) is -285.4%. The historical average is -256.0%.
Is NRXS stock overvalued?
Based on historical data, NeurAxis, Inc. is trading at a P/E of -9.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are NeurAxis, Inc.'s profit margins?
NeurAxis, Inc. has 84.2% gross margin and -219.4% operating margin.